No products in the cart.
#VisualAbstract: Pembrolizumab-based therapy is more effective with increasing PD-L1 expression in head and neck squamous cell carcinomas
Click to read this study in the Journal of Clinical Oncology.
Tag: immunotherapy
#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.
Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease
1. There was no significant difference in efficacy of ICIs in cancer patients with or without AID. 2. Immune-related toxic ...
#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...
Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies
1. Compared to placebo, children who received peanut oral immunotherapy experienced significantly greater desensitization and remission. 2. Younger age at ...
#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma
Click to read this study in Lancet Oncology.
#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
Click to read this study in JAMA Network Open.
Nivolumab plus ipilimumab improved long-term survival in patients with advanced melanoma
1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% ...
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.